Irinotecan and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. A phase II study of the Hellenic Cooperative Oncology Group

Anticancer Research

Volumn 22, Issue 6 B, 2002, Pages 3501-3506

  Pectasides, D ^a,d   Fountzilas, G ^b   Rigopoulos, A ^c   Bountouroglou, N G ^a   Koutras, A ^c   Glotsos, J ^a   Onyenadum, A ^c   Makatsoris, Th ^c   Kalofonos, H P ^c  

^a METAXA CANCER HOSPITAL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^d Hellenic Cooperative Oncology Group   (Greece)

Author keywords

Chemotherapy; Irinotecan; Refractory advanced NSCLC; Vinorelbine

Indexed keywords

ANTIBIOTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; NAVELBINE; PLATINUM DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTIBIOTIC THERAPY; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HEMOPTYSIS; HOSPITALIZATION; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NEUROTOXICITY; NEUTROPENIA; OUTCOMES RESEARCH; OUTPATIENT CARE; PAIN; PERFORMANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SYMPTOM; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; VINBLASTINE;

EID: 0036875568     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Shepherd F, Dansey J, Ramlau R et al.: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-2103, 2000.
2. Pronzato P, Landucci M, Vaira F et al.: Failure of vinorelbine responses in pretreated non-small cell lung cancer patients. Anticancer Res 14: 1413-1416, 1994.
3. Rinaldi M, Della Giulia M, Venturo I et al.: Vinorelbine (VNB) as single agent in the treatment of advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 13: 360, 1994 (abstr 12).
4. Fossella FV, De Vore R, Kerr RN et al.: Randomized phase II trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum containing chemotherapy regimens. J Clin Oncol 18: 2354-2362, 2000.
5. Santoro A, Maiorino L and Santoro M: Second-line with vinorelbine in the weekly monochemotherapy for the treatment of advanced non-small cell lung cancer. Lung Cancer 11 (Suppl 1), (abstr 130), 1994.
6. Burris III HA and Fields S: Summary of data from in vitro and phase I vinorelbine (navelbine) studies. Semin Oncol 21 (Suppl 10): 14-20, 1994.
7. Mogi H, Hasegawa Y, Watanabe A et al.: Combination effects of cisplatin, vinorelbine and irinotecan in non-small cell lung cancer cell lines in vitro. Cancer Chemother Pharmacol 39: 199-204, 1997.
8. Shimada Y, Rothenberg ML, Hilsenbeck SG et al.: Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drugs 5: 202-206, 1994.
9. Tamura K, Takada M, Kawase I et al.: Enhancement of tumor radioresponse by irinotecan in human lung tumor xenografts. Jpn J Cancer Res 88: 218-223, 1997.
10. Fukuoka M, Niitani H, Suzuki A et al.: A phase II study of CPT-11, a new derivative of camptothecin for previously untreated non-small cell lung cancer. J Clin Oncol 10: 16-20, 1992.
11. Duillard JY, Ibrahim N, Riviere A et al.: Phase II study of CPT-11 (irinotecan) in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14: 365, 1995 (abstr 1118).
12. Baker L, Khan R, Lynch T et al.: Phase II study of CPT-11 (irinotecan) in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 16: 461a 1997 (abstr 1658).
13. Nakai H, Fukuoka M, Furuse K et al.: An early phase II study of CPT-11 in primary lung cancer. Gan To Kagaku Ryobo 18: 607-612, 1991.
14. Negoro S, Fukuoka M, Niitani H et al.: A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group. To Kagaku Ryobo 18: 1013-1019, 1991.
15. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment [WHO Offset Publication (No 48)]. Geneva, Switzerland, World Health Organization, 1979.
16. Kaplan EL and Meier P: Non-parametric estimation for complete observations. J Am Stat Assoc 53: 457-481, 1958.
17. Fossella FV, Lee JS and Hong WK. Management strategies for recurrent non-small cell lung cancer. Semin Oncol 24: 455-462 1955.
18. Cao MG, Salgado E, Aramendia JM et al.: Second-line treatment with irinotecan (CPT-11) and navelbine (NVB) for non-small cell lung cancer. Proc Am Soc Clin Oncol 19: 540a, 2000 (abstr 2127).
19. Crino L, Mosconi AM, Scagliotti G et al.: Gemcitabine as second-line treatment for advanced non-small cell lung cancer. A phase II trial. J Clin Oncol 17: 2081-2085, 1999.
20. Rosvold E, Langer CJ, Schilder R et al.: Salvage therapy with gemcitabine in advanced non-small cell lung cancer (NSCLC) progressing after prior carboplatin-paclitaxel. Proc Am Soc Clin Oncol 17: 467a, 1998 (abstr 1797).
21. Guerra JA, Lianes P, Paz-Ares I et al.: Efficacy and toxicity profile of gemcitabine in previously treated patients with advanced non-small cell lung cancer. Lung Cancer 18(Suppl 1): 28, 1997 (abstr 99).
22. Garfield DH, Dakhil SR, Whitaker TL et al.: Phase II randomized multicenter trial of two close schedules of gemcitabine as second line therapy in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 17: 484a, 1998 (abstr 1863).
23. Fossella FV, DeVore R, Kerr RN et al.: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18: 2354-2362, 2000.
24. Gian V, Hainsworth JD, Burris HA et al.: Combination of gemcitabine and vinorelbine in the second line treatment of non-small cell lung cancer (NSCLC). A phase II study of the Minnie Pearl Cancer Research Network. Proc Am Soc Clin Oncol 18: 505a, 1999(abstr1949).
25. Barr F, Minsky H, Clinthorne D et al.: A phase II study of gemcitabine and vinorelbine salvage chemotherapy for taxanes non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 18: 496a, 1999(abstr 1914).
26. Herbst RS, Khuri FR, Jung M et al.: Phase II study of combination gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer. Proc Am Soc Clin Oncol 19: 462a, 1999(abstr 1782).
27. Pectasides D, Kalofonos HP, Samantas E et al.: An outpatient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic Co-Operative Oncology Group. Anticancer Res 21: 3005-3010, 2001.
28. Rothenberg ML: CPT-11: An original spectrum of clinical activity. Semin Oncol 23(Suppl 3): 21-26, 1996.
29. Klastersky J: New drug therapy of non-small cell lung cancer. Lung Cancer 11(Suppl 3): 139-149, 1994.
30. Crawford J: Update: Vinorelbine (Navelbine) in non-small cell lung cancer. Semin Oncol 23(Suppl 5): 2-7, 1996.
31. Abigerges D, Armada JP, Chabot GG et al.: Irinotecan (CPT-11) high dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Instit 86: 446-449, 1994.